Updates on Biotechnology Industry Stocks - BioCryst Pharma, Incyte, bluebird bio, Cempra, and BioLineRx

News provided by

www.erionline.net

Sep 11, 2015, 09:30 ET

NEW YORK, September 11, 2015 /PRNewswire/ --

Equity Research Institute has initiated coverage on the following equities: BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), Incyte Corporation (NASDAQ: INCY), bluebird bio Inc. (NASDAQ: BLUE), Cempra Inc. (NASDAQ: CEMP), and BioLineRx Ltd (NASDAQ: BLRX). Free research report on BioCryst Pharma can be accessed at https://www.erionline.net/reports?keyword=BCRX On Thursday, September 10, 2015, the NASDAQ Composite ended at 4,796.25, up 0.84%, the Dow Jones Industrial Average edged 0.47% higher, to finish the day at 16,330.40, and the S&P 500 closed at 1,952.29, up 0.53%. The gains were broad based as eight out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.

BioCryst Pharmaceuticals Inc.'s stock surged 6.13%, to close Thursday's session at $12.47. The stock recorded a trading volume of 1.01 million shares, below its three months average volume of 1.05 million shares. Over the last one month and since the start of this year, BioCryst Pharmaceuticals Inc.'s shares have advanced 9.00% and 2.55%, respectively. However, the stock has declined 2.20% in the previous three months. The company is trading 8.13% above its 200-day moving average. Furthermore, BioCryst Pharmaceuticals Inc.'s stock has a Relative Strength Index (RSI) of 51.10. Sign up and read the free notes on BCRX at:

https://www.erionline.net/reports?keyword=BCRX

Incyte Corp.'s stock finished Thursday's session 5.33% higher at $124.50. A total of 1.79 million shares were traded, which was above its three months average volume of 1.15 million shares. Over the last one month and the previous three months, Incyte Corp.'s shares have advanced 19.47% and 17.33%, respectively. Furthermore, the stock has surged 70.29% since the beginning of 2015. The company's shares are trading above their 50-day and 200-day moving averages by 13.15% and 31.24%, respectively. Incyte Corp.'s stock traded at a PE ratio of 3,112.50 and has an RSI of 60.28. The complimentary notes on INCY can be downloaded in PDF format at:

https://www.erionline.net/reports?keyword=INCY

On Thursday, shares in bluebird bio Inc. ended the session 0.46% higher at $130.91. The stock reported a trading volume of 0.47 million shares, below its three months average volume of 0.91 million shares. bluebird bio Inc.'s shares have plummeted 3.66% in the last one month and 29.69% in the previous three months. However, the stock has surged 42.73% on YTD basis. The company is trading 3.70% above its 200-day moving average. Moreover, shares of bluebird bio Inc. have an RSI of 44.25. Register for free on Equity Research Institute and access the latest research on BLUE at:

https://www.erionline.net/reports?keyword=BLUE

Cempra Inc.'s stock edged 0.97% lower, to close the day at $33.58. The stock recorded a trading volume of 0.62 million shares, below its three months average volume of 0.86 million shares. Over the last one month and over the past three months, Cempra Inc.'s shares have lost 11.72% and 3.84%, respectively. However, the stock has surged 42.83% since the start of this year. The company's shares are trading 4.65% above their 200-day moving average. Additionally, Cempra Inc. has an RSI of 43.12. The complete research on CEMP is available for free at:

https://www.erionline.net/reports?keyword=CEMP

On Thursday, shares in BioLineRx Ltd recorded a trading volume of 0.37 million shares, lower than their three months average volume of 0.80 million shares. The stock ended the day 1.72% higher at $1.77. Although, BioLineRx Ltd's stock has declined 8.29% in the previous three months, it has gained 20.41% in the last one month and 9.26% on YTD basis. The company is trading below its 50-day and 200-day moving averages by 2.68% and 7.99%, respectively. Furthermore, shares of BioLineRx Ltd have an RSI of 58.57. Free in-depth research on BLRX is available at:

https://www.erionline.net/reports?keyword=BLRX

About Equity Research Institute:

Equity Research Institute ("ERI") produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. ERI has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

ERI has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer"). Rohit Tuli, a CFA® charter holder (the "CFA®"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on sound investment judgment and publicly available information which is believed to be reliable. The Reviewer and the CFA® have not performed any independent investigations or forensic audits to validate the information herein. Unless otherwise noted, any content outside of this document has no association with the Author, the Reviewer, or the CFA® (collectively referred to as the "Production Team") in any way. The Production Team is compensated on a fixed monthly basis and do not hold any positions of interest in any of the securities mentioned herein.

NO WARRANTY

ERI, the Author, the Reviewer and the CFA® (collectively referred to as the "Publishers") are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by the Publishers whatsoever for any direct, indirect or consequential loss arising from the use of this document. The Publishers expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, the Publishers do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither ERI nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.erionline.net.

RESTRICTIONS

ERI is not available to residents of Belarus, Cuba, Canada, Iran, North Korea, Sudan, Syria or Somalia. Do not send email to robottrap (at) erionline.net.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE www.erionline.net